Laekna is monetizing an oncology asset by licensing ex-China rights to LAE-118, a PI3Kα pan-mutant selective inhibitor, to U.S.-based Vasque Bio in a deal valued at up to $527 million. The transaction adds to the broader asset monetization strategy for the Shanghai company as it funds and accelerates its oncology and metabolic pipeline. In parallel, GSK agreed to acquire Nuvalent for $10.6 billion, aiming to strengthen its precision oncology portfolio with multiple non-small cell lung cancer assets in the company’s pipeline. The deal includes products with FDA review decision dates later this year and emphasizes next-generation targeted approaches intended to address CNS penetration and resistance mutations. Together, the transactions show continued high-stakes consolidation and platform-value extraction in oncology as large pharma adds late-stage or near-registration candidates and specialists monetize differentiated small-molecule oncology programs.